胰腺癌是预后极差的一种消化道恶性肿瘤,因其发现较晚,对于放化疗不甚敏感,导致5年生存率不足5%,随着科学技术的发展,miRNA在癌症中的关键作用已被证实。miRNA也迅速成为开发新型抗癌疗法的有前途的靶标,其中miR-107及其下游的可能靶基...胰腺癌是预后极差的一种消化道恶性肿瘤,因其发现较晚,对于放化疗不甚敏感,导致5年生存率不足5%,随着科学技术的发展,miRNA在癌症中的关键作用已被证实。miRNA也迅速成为开发新型抗癌疗法的有前途的靶标,其中miR-107及其下游的可能靶基因ZFPM2已被发现与多种癌症存在关系,但在胰腺癌的研究仍有空缺,对于改善目前胰腺癌早期发现及治疗困境具有一定的潜在价值。本文通过综述现有的关于miR-107与ZFPM2在其他肿瘤中的研究现状,为胰腺癌的早期发现及靶向治疗提供新的思路。Pancreatic cancer is a highly malignant digestive tract tumor with an extremely poor prognosis. Due to its late detection and limited sensitivity to radiotherapy and chemotherapy, the 5-year survival rate is less than 5%. With the advancement of science and technology, the critical role of miRNA in cancer has been confirmed. miRNA has rapidly emerged as promising targets for the development of novel anti-cancer therapies. Among them, miR-107 and its potential downstream target gene ZFPM2 have been found to be associated with various cancers, but research on their roles in pancreatic cancer remains limited. They hold potential value for improving the current challenges in early detection and treatment of pancreatic cancer. This article reviews the existing research on miR-107 and ZFPM2 in other tumors, aiming to provide new insights for early detection and targeted therapy of pancreatic cancer.展开更多
Breast phyllodes tumor(PT)is a rare fibroepithelial neoplasm with potential malignant behavior.Long non-coding RNAs(lncRNAs)play multifaceted roles in various cancers,but their involvement in breast PT remains largely...Breast phyllodes tumor(PT)is a rare fibroepithelial neoplasm with potential malignant behavior.Long non-coding RNAs(lncRNAs)play multifaceted roles in various cancers,but their involvement in breast PT remains largely unexplored.In this study,microarray was leveraged for the first time to investigate the role of lncRNA in PT.We identified lncRNA ZFPM2-AS1 was significantly upregulated in malignant PT,and its overexpression endowed PT with high tumor grade and adverse prognosis.Furthermore,we elucidated that ZFPM2-AS1 promotes the proliferation,migration,and invasion of malignant PT in vitro.Targeting ZFPM2-AS1 through nanomaterial-mediated siRNA delivery in patient-derived xenograft(PDX)model could effectively inhibit tumor progression in vivo.Mechanistically,our findings showed that ZFPM2-AS1 is competitively bound to CDC42,inhibiting ACK1 and STAT1 activation,thereby launching the transcription of TNFRSF19.In conclusion,our study provides evidence that ZFPM2-AS1 plays a pivotal role in the pathogenesis of breast PT,and suggests that ZFPM2-AS1 could serve as a prognostic indicator for patients with PT as well as a promising novel therapeutic target.展开更多
文摘胰腺癌是预后极差的一种消化道恶性肿瘤,因其发现较晚,对于放化疗不甚敏感,导致5年生存率不足5%,随着科学技术的发展,miRNA在癌症中的关键作用已被证实。miRNA也迅速成为开发新型抗癌疗法的有前途的靶标,其中miR-107及其下游的可能靶基因ZFPM2已被发现与多种癌症存在关系,但在胰腺癌的研究仍有空缺,对于改善目前胰腺癌早期发现及治疗困境具有一定的潜在价值。本文通过综述现有的关于miR-107与ZFPM2在其他肿瘤中的研究现状,为胰腺癌的早期发现及靶向治疗提供新的思路。Pancreatic cancer is a highly malignant digestive tract tumor with an extremely poor prognosis. Due to its late detection and limited sensitivity to radiotherapy and chemotherapy, the 5-year survival rate is less than 5%. With the advancement of science and technology, the critical role of miRNA in cancer has been confirmed. miRNA has rapidly emerged as promising targets for the development of novel anti-cancer therapies. Among them, miR-107 and its potential downstream target gene ZFPM2 have been found to be associated with various cancers, but research on their roles in pancreatic cancer remains limited. They hold potential value for improving the current challenges in early detection and treatment of pancreatic cancer. This article reviews the existing research on miR-107 and ZFPM2 in other tumors, aiming to provide new insights for early detection and targeted therapy of pancreatic cancer.
基金supported by the National Natural Science Foundation of China(82173054,82222029,82203085)the Guangdong Basic and Applied Basic Research Foundation(2022B1515020048,2022B1515020101,China)Guangzhou Science,Technology and Innovation Commission(202102010148,China).
文摘Breast phyllodes tumor(PT)is a rare fibroepithelial neoplasm with potential malignant behavior.Long non-coding RNAs(lncRNAs)play multifaceted roles in various cancers,but their involvement in breast PT remains largely unexplored.In this study,microarray was leveraged for the first time to investigate the role of lncRNA in PT.We identified lncRNA ZFPM2-AS1 was significantly upregulated in malignant PT,and its overexpression endowed PT with high tumor grade and adverse prognosis.Furthermore,we elucidated that ZFPM2-AS1 promotes the proliferation,migration,and invasion of malignant PT in vitro.Targeting ZFPM2-AS1 through nanomaterial-mediated siRNA delivery in patient-derived xenograft(PDX)model could effectively inhibit tumor progression in vivo.Mechanistically,our findings showed that ZFPM2-AS1 is competitively bound to CDC42,inhibiting ACK1 and STAT1 activation,thereby launching the transcription of TNFRSF19.In conclusion,our study provides evidence that ZFPM2-AS1 plays a pivotal role in the pathogenesis of breast PT,and suggests that ZFPM2-AS1 could serve as a prognostic indicator for patients with PT as well as a promising novel therapeutic target.
